Appendix Table 5.
Time to benefit for lung cancer screening to prevent all-cause death at specific thresholds of absolute risk reduction.
| Trial (Publication) | Time to benefit in years (95% CI) | ||
|---|---|---|---|
| ARR = 0.0005a | ARR = 0.001b | ARR = 0.002c | |
| LUSI (Becker 2020) | 2.1 (0.2–12.0) | 4.2 (0.3–12.0) | 8.5 (0.7–12.0) |
| UKLS (Field 2021) | All-cause mortality not reported for all participants | All-cause mortality not reported for all participants | All-cause mortality not reported for all participants |
| NELSON (De Koning 2020) | 1.7 (0.6–12.0) | 3.3 (0.9–12.0) | 12.0 (1.6–12.0) |
| DANTE (Infante 2015) | 3.2 (0.3–12.0) | 3.83 (0.3–12.0) | 4.8 (0.7–12.0) |
| NLST (NLST 2019) | 1.7 (1.0–12.0) | 2.8 (1.7–12.0) | 4.7 (2.8–12.0) |
| ITALUNG (Paci 2017) | 0.5 (0.2–7.8) | 0.8 (0.3–11.1) | 1.4 (0.6–12.0) |
| MILD (Pastorino 2019) | 3.9 (0.5–12.0) | 4.8 (0.8–12.0) | 5.8 (1.5–12.0) |
| DLCST (Wille 2016) | 11.3 (2.9–12.0) | 11.7 (3.8–12.0) | 12.0 (4.8–12.0) |
| Summary | 2.5 (1.1–5.6) | 3.8 (1.9–7.3) | 5.8 (3.1–10.8) |
NLST results were derived using individual data from the original dataset. The upper limit of 95% confidence interval does not exceed 12.0 years due to censoring at 12 years of follow-up.
ARR=absolute risk reduction. CI=confidence interval. NA=Not applicable.
a
Time to prevent one all-cause death per 2000 people screened with LDCT.
b
Time to prevent one all-cause death per 1000 people screened with LDCT.
c
Time to prevent one all-cause death per 500 people screened with LDCT.